JP7541505B2 - アルツハイマー病の治療及び予防方法 - Google Patents

アルツハイマー病の治療及び予防方法 Download PDF

Info

Publication number
JP7541505B2
JP7541505B2 JP2021503770A JP2021503770A JP7541505B2 JP 7541505 B2 JP7541505 B2 JP 7541505B2 JP 2021503770 A JP2021503770 A JP 2021503770A JP 2021503770 A JP2021503770 A JP 2021503770A JP 7541505 B2 JP7541505 B2 JP 7541505B2
Authority
JP
Japan
Prior art keywords
months
subject
composition
determined
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532126A (ja
JPWO2020023530A5 (enExample
Inventor
ジョアン ラスマン，
チャド ジェイ． スワンソン，
ヨン チャン，
ショブハ ダーダ，
ジンピン ワン，
リン クレイマー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2021532126A publication Critical patent/JP2021532126A/ja
Publication of JPWO2020023530A5 publication Critical patent/JPWO2020023530A5/ja
Priority to JP2024077300A priority Critical patent/JP2024112859A/ja
Application granted granted Critical
Publication of JP7541505B2 publication Critical patent/JP7541505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021503770A 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法 Active JP7541505B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077300A JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077300A Division JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Publications (3)

Publication Number Publication Date
JP2021532126A JP2021532126A (ja) 2021-11-25
JPWO2020023530A5 JPWO2020023530A5 (enExample) 2022-07-28
JP7541505B2 true JP7541505B2 (ja) 2024-08-28

Family

ID=67551415

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503770A Active JP7541505B2 (ja) 2018-07-24 2019-07-23 アルツハイマー病の治療及び予防方法
JP2024077300A Pending JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077300A Pending JP2024112859A (ja) 2018-07-24 2024-05-10 アルツハイマー病の治療及び予防方法

Country Status (13)

Country Link
US (1) US20210324056A1 (enExample)
EP (1) EP3826674A2 (enExample)
JP (2) JP7541505B2 (enExample)
KR (1) KR20210039402A (enExample)
CN (2) CN112805031A (enExample)
AU (1) AU2019309938A1 (enExample)
BR (1) BR112021001272A2 (enExample)
CA (1) CA3107370A1 (enExample)
IL (3) IL280315B2 (enExample)
MX (1) MX2021000778A (enExample)
PH (1) PH12021500006A1 (enExample)
TW (1) TW202019471A (enExample)
WO (1) WO2020023530A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
HRP20251087T1 (hr) * 2020-03-20 2025-11-07 Eisai R&D Management Co., Ltd. Formulacije visoke koncentracije anti-amiloidnih beta peptidnih protofibrilnih protutijela i postupci njihove upotrebe
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
US20230302009A1 (en) * 2020-08-12 2023-09-28 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022410770A1 (en) * 2021-12-17 2024-06-13 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081460A1 (en) 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RS51723B2 (sr) * 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
PL2448968T3 (pl) 2009-06-29 2021-09-13 Bioarctic Ab Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
CN102869680B (zh) 2010-02-26 2016-10-05 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用
SG191710A1 (en) 2011-01-21 2013-08-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
PE20170768A1 (es) 2014-07-10 2017-07-04 Eisai Randd Man Co Ltd Anticuerpos de union a protofibrillas ab mejorados
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
EP3454904B1 (en) * 2016-05-13 2022-12-14 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081460A1 (en) 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
「EISAI AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS OF THE FINAL ANALYSIS FOR BAN2401 AT 18 MONTHS」のインターネットアーカイブ [オンライン]，Eisai Co., Ltd. & Biogen Inc.，2018年07月10日，[検索日：2023年8月4日], <URL: https://web.archive.org/web/20180710034023/https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-positive-topline-results-final>

Also Published As

Publication number Publication date
IL280315B1 (en) 2024-02-01
BR112021001272A2 (pt) 2021-04-27
CN118924896A (zh) 2024-11-12
EP3826674A2 (en) 2021-06-02
IL310132B1 (en) 2025-11-01
MX2021000778A (es) 2021-03-31
IL323583A (en) 2025-11-01
IL280315B2 (en) 2024-06-01
IL310132A (en) 2024-03-01
JP2024112859A (ja) 2024-08-21
JP2021532126A (ja) 2021-11-25
CA3107370A1 (en) 2020-01-30
CN112805031A (zh) 2021-05-14
WO2020023530A2 (en) 2020-01-30
KR20210039402A (ko) 2021-04-09
PH12021500006A1 (en) 2021-09-13
WO2020023530A3 (en) 2020-03-12
IL280315A (en) 2021-03-25
AU2019309938A1 (en) 2021-03-11
US20210324056A1 (en) 2021-10-21
TW202019471A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
JP7541505B2 (ja) アルツハイマー病の治療及び予防方法
CA3158513A1 (en) Methods for treating alzheimer&#39;s disease
US20250163135A1 (en) Biomarkers for alzheimer&#39;s disease treatment
JP2018111723A (ja) アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
CN117244056A (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
CA3230148A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025539394A (ja) タウｐｅｔレベルを使用する治療の方法
RU2832167C2 (ru) Способы лечения и предупреждения болезни альцгеймера
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
CN118786141A (zh) 使用p-tau181水平的治疗方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
AU2024286486A1 (en) Methods of treatment using an anti-abeta protofibril antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240816

R150 Certificate of patent or registration of utility model

Ref document number: 7541505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150